Helen Tayton-Martin – VJRegenMed

Adaptimmune: SPEAR T-cells

admin_vjr_user — Tue, 03 Nov 2020 17:39:49 +0000

TCR T-cell therapies (SPEAR T-cells) hold the potential to treat a wide range of cancers. In this video, Helen Tayton-Martin, Chief Business Officer, Adaptimmune, Oxford, UK. discusses the SPEAR T-cells currently under development with Adaptimmune. Dr Taytor-Martin goes on to discuss Adaptimmune’s partnership with GlaxoSmithKline (GSK) and recent advances such as the SURPASS trial (NCT04044859) which investigated ADP-A2M4CD8 in HLA-A2+ subjects with MAGE-A4 positive tumors. This interview took place during the 2020 Meeting on the Mesa congress.

T-cells: challenges in bringing to market

admin_vjr_user — Tue, 03 Nov 2020 17:39:49 +0000

T-cell therapies present a whole host of challenges with regards to manufacturing, distribution and ultimately bringing into a clinical setting. Helen Tayton-Martin, PhD, Adaptimmune, Oxford, UK, talks on the challenges in bringing to market and how Adaptimmune has taken action to circumvent these bottlenecks. This interview took place during the 2020 Meeting on the Mesa congress.

The cell therapy landscape: disruptive technologies

admin_vjr_user — Tue, 03 Nov 2020 17:39:49 +0000

Helen Tayton-Martin, PhD, Adaptimmune, Oxford, UK, discusses disruptive technologies that may change the cell therapy landscape. Specifically discussed is the formation of an off-the-shelf T-cell product able to treat solid tumors with the same potency and efficacy seen with current cellular therapies. This interview took place during the 2020 Meeting on the Mesa congress.

The potential of RegenMed in the oncology space

admin_vjr_user — Tue, 03 Nov 2020 17:39:49 +0000

Helen Tayton-Martin, PhD, Adaptimmune, Oxford, UK, speaks on the reformative nature of regenerative medicine. Dr Taytor-Martin highlights cell and gene therapies in the oncology setting, and how these technologies may represent a potential paradigm shift in the future. This interview took place during the 2020 Meeting on the Mesa congress.